Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03666923 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
A Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT03666923: Completed Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema, sponsored by ThromboGenics.
NCT03666923 is a Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema that has completed, run by ThromboGenics. The registered enrollment target is 12 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03666923, a Phase 1 study of Diabetes Mellitus and Diabetic Macular Edema, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
Conditions Studied
Interventions
- DRUG THR-687 dose level 1
- DRUG THR-687 dose level 2
- DRUG THR-687 dose level 3
Study Locations (7)
Texas
- Retina Research Institute of Texas - Abilene
- Valley Retina Institute, PA - McAllen
Arizona
- Retina Consultants of Arizona - Phoenix
Florida
- Center for Retina and Macular Disease - Winter Haven
Indiana
- Midwest Eye Institute - Indianapolis
Nevada
- Sierra Eye Associates - Reno
South Carolina
- Palmetto Retinal Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 1 |
What the finished NCT03666923 record still lists
NCT03666923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which THR-687 dose level 1 is the first listed.
NCT03666923 lists 7 locations in 6 states (Texas, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT03666923 about?
NCT03666923 is a clinical study titled "A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)". This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
What is the current status of trial NCT03666923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-09-17. Estimated completion is 2019-11-20.
What conditions does trial NCT03666923 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT03666923?
The interventions under investigation include: THR-687 dose level 1 (DRUG), THR-687 dose level 2 (DRUG), THR-687 dose level 3 (DRUG).
Who is sponsoring clinical trial NCT03666923?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03666923 being conducted?
This trial has 7 study locations across Arizona, Florida, Indiana, Nevada, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03666923's enrollment target sits among peer trials
12 202nd of 208 higher than 5 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
RECRUITING · Phase 1
-
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
-
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
COMPLETED · Phase 1
-
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
COMPLETED · Phase 1
-
Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI